Novartis AG (NVS) – Cosentyx and Entresto are the growth drivers of NVS

in , on June 14, 2019

Novartis revenues grew by 2% to $11.1bn in Q1FY19 with the Mayzent launch, successful Alcon spin-off, and strong operational execution. Core operating income grew at 18% and core margin expanding by 2.6% during the quarter. Net income grew by 4% due to the impact of a net impairment charge and lower divestment gains.

Number of Pages – 48


Executive Summary

Financial Statements

–Income Statement and Forecast

–Balance Sheet

–Cash Flow

–Q1FY19 Results – Overview

–Q1FY19 – Segment Performance

–Q1FY19 – R&D Update

–FY19 Guidance and Conclusion

–IFRS to Non-IFRS reconciliation

Historical Performance

–Key Ratios

–Profitability Ratios, Asset Turnover Ratio, Growth Ratio

–Per Share Items and Key Ratios

–Key Cash Flow Items

–P/E Band

Product Performance and Key Developments



–Key Developments

Valuation and Consensus Performance

–Relative Valuation

–Analyst Recommendations

Market Price Performance

CrispIdea Coverage Chart

Release Information

  • Released

    June 14, 2019

  • Last Updated

    June 27, 2019